0000000000353562

AUTHOR

Martina Alvarez

showing 2 related works from this author

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Dia…

2019

Circulating tumor DNA (ctDNA) has emerged as a non-invasive &ldquo

Oncologymedicine.medical_specialtymolecular profilinglcsh:MedicineDNA sequencing03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinemedicineMammographyLiquid biopsycirculating tumor DNA (ctDNA)GeneLymph node030304 developmental biology0303 health sciencesmedicine.diagnostic_testliquid biopsybusiness.industrylcsh:RGeneral MedicineAmpliconmedicine.diseasemedicine.anatomical_structure030220 oncology & carcinogenesisImmunohistochemistrybusinessearly-stage cancer
researchProduct

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.

2018

Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any differences in response to neoadjuvant chemotherapy among them. We determined Lehmann subtypes by gene expression profiling in paraffined pre-treatment tumor biopsies from 125 TNBC patients treated with neoadjuvant anthracyclines and/or taxanes +/- carboplatin. We explored the clinicopathological characteristics of Lehmann subtypes and their association with the pathologic complete response (pCR) to different treatments. The g…

0301 basic medicineOncologymedicine.medical_specialtysubtypingmedicine.medical_treatmentCarboplatin03 medical and health scienceschemistry.chemical_compoundpathologic complete responseSubtyping0302 clinical medicineInternal medicinePathologic complete responsemedicineClinical significanceTriple negative breast cancerneoadjuvant therapyReceptorTriple-negative breast cancerNeoadjuvant therapyChemotherapybusiness.industryPhenotypeCarboplatinGene expression profiling030104 developmental biologyOncologychemistry030220 oncology & carcinogenesistriple negative breast cancercarboplatinNeoadjuvant therapybusinessResearch Paper
researchProduct